Drug Profile
Cord mesenchymal stem cell therapy - Beike Biotechnology
Alternative Names: Human umbilical cord mesenchymal stem cells (hUC-MSC) - Beike Biotechnology; UC-MSC; UC-MSCT; Wharton's Jelly-derived mesenchymal stem cells (WJMSC) - Beike BiotechnologyLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Beike Biotechnology
- Developer Beike Biotechnology; Chinese PLA General Hospital
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Duchenne muscular dystrophy; Multiple sclerosis; Myocardial infarction; Primary ovarian insufficiency; Spinocerebellar degeneration; Systemic lupus erythematosus
Most Recent Events
- 26 Apr 2019 Discontinued - Phase-I/II for Primary ovarian insufficiency in China (Parenteral)
- 26 Apr 2019 Discontinued - Phase-II for Duchenne muscular dystrophy in China (IM)
- 26 Apr 2019 Discontinued - Phase-II for Multiple sclerosis in China (IM)